189 related articles for article (PubMed ID: 14769521)
1. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics.
Legroux-Gerot I; Catanzariti L; Marchandise X; Duquesnoy B; Cortet B
Joint Bone Spine; 2004 Jan; 71(1):51-5. PubMed ID: 14769521
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria.
Laroche M; Mazières B
Clin Exp Rheumatol; 1998; 16(1):109-10. PubMed ID: 9543581
[No Abstract] [Full Text] [Related]
3. Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels.
Sigurdsson G; Franzson L
J Intern Med; 2001 Jul; 250(1):51-6. PubMed ID: 11454142
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.
Ghannam NN; Hammami MM; Bakheet SM; Khan BA
Calcif Tissue Int; 1999 Jul; 65(1):23-8. PubMed ID: 10369729
[TBL] [Abstract][Full Text] [Related]
5. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
[TBL] [Abstract][Full Text] [Related]
6. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.
Reid IR; Ames RW; Orr-Walker BJ; Clearwater JM; Horne AM; Evans MC; Murray MA; McNeil AR; Gamble GD
Am J Med; 2000 Oct; 109(5):362-70. PubMed ID: 11020392
[TBL] [Abstract][Full Text] [Related]
7. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
8. [Diuretics and osteoporosis].
Rejnmark L; Mosekilde L; Andreasen F
Nord Med; 1998 Feb; 113(2):53-9. PubMed ID: 9497618
[TBL] [Abstract][Full Text] [Related]
9. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group.
Cauley JA; Cummings SR; Seeley DG; Black D; Browner W; Kuller LH; Nevitt MC
Ann Intern Med; 1993 May; 118(9):666-73. PubMed ID: 8489642
[TBL] [Abstract][Full Text] [Related]
10. Thiazides and seasonal bone change in healthy postmenopausal women.
Dawson-Hughes B; Harris S
Bone Miner; 1993 Apr; 21(1):41-51. PubMed ID: 8324419
[TBL] [Abstract][Full Text] [Related]
11. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
12. [Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis].
Suárez Fernández C; Ruilope Urioste LM
An Med Interna; 1996 Aug; 13(8):401-6. PubMed ID: 8983370
[TBL] [Abstract][Full Text] [Related]
13. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
14. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
15. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
[TBL] [Abstract][Full Text] [Related]
16. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
17. Management of male osteoporosis.
Cortet B; Vasseur J; Grardel B; Catanzariti L; Marchandise X; Delcambre B
Joint Bone Spine; 2001 May; 68(3):252-6. PubMed ID: 11394626
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
19. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
